Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MBX Biosciences, Inc. Common Stock (MBX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: MBX (1-star) is a SELL. SELL since 3 days. Profits (1.05%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $37.57
1 Year Target Price $37.57
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -18.54% | Avg. Invested days 28 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 443.78M USD | Price to earnings Ratio - | 1Y Target Price 37.57 |
Price to earnings Ratio - | 1Y Target Price 37.57 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 4.81 - 27.50 | Updated Date 08/15/2025 |
52 Weeks Range 4.81 - 27.50 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.24 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.7632 | Actual -0.58 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.75% | Return on Equity (TTM) -56.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 219518969 | Price to Sales(TTM) - |
Enterprise Value 219518969 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 33593900 | Shares Floating 13779868 |
Shares Outstanding 33593900 | Shares Floating 13779868 | ||
Percent Insiders 3.1 | Percent Institutions 110.03 |
Upturn AI SWOT
MBX Biosciences, Inc. Common Stock
Company Overview
History and Background
MBX Biosciences is a clinical-stage biopharmaceutical company focusing on the development of peptide therapeutics to treat endocrine disorders. Founded in 2016, it is headquartered in Indianapolis, Indiana. The company is still young, focused on preclinical and clinical development.
Core Business Areas
- Peptide Therapeutics Development: MBX Biosciences develops peptide therapeutics targeting G protein-coupled receptors (GPCRs) relevant to endocrine disorders. Their focus includes optimized potency, long duration of action, and improved manufacturability.
- Precision Endocrine Peptide (PEP) Platform: MBX uses a proprietary PEP platform that identifies and develops improved peptide therapeutic candidates with better therapeutic properties.
Leadership and Structure
The leadership team comprises experienced professionals in peptide engineering, endocrinology, and drug development. The company is structured around research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- MBX-214: MBX-214 is their lead clinical-stage product candidate for the treatment of hypoparathyroidism. Currently in Phase 2 trials. Market share data is unavailable as the product isn't yet commercialized. Competitors are Ascendis Pharma (TransCon PTH) and Takeda (Natpara), though Natpara is only available under strict medical supervision.
- Preclinical Programs: MBX Biosciences has multiple earlier-stage programs targeting other endocrine disorders, however no specifics are available.
Market Dynamics
Industry Overview
The biopharmaceutical industry, specifically peptide therapeutics, is growing, driven by advancements in drug delivery and increased understanding of disease mechanisms. The endocrine disorders market is a significant segment with unmet needs.
Positioning
MBX Biosciences is positioned as an innovator in peptide therapeutics for endocrine disorders, leveraging its PEP platform to develop differentiated products.
Total Addressable Market (TAM)
The total addressable market (TAM) for hypoparathyroidism is estimated to be billions of dollars globally. MBX Biosciences aims to capture a significant share with MBX-214. The TAM for all endocrine disorders is substantially larger.
Upturn SWOT Analysis
Strengths
- Proprietary PEP platform
- Focus on endocrine disorders with unmet needs
- Experienced leadership team
- Lead clinical-stage product candidate (MBX-214)
Weaknesses
- Early-stage company with limited revenue
- Reliance on clinical trial success
- Limited resources compared to larger pharmaceutical companies
- Limited data about MBX's financial situation
Opportunities
- Successful clinical trials leading to regulatory approvals
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline to other endocrine disorders
- Advancements in peptide drug delivery technologies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expirations
- Market access challenges
Competitors and Market Share
Key Competitors
- ASND
- TAK
Competitive Landscape
MBX Biosciences aims to compete by developing more effective and convenient peptide therapeutics compared to existing treatments.
Growth Trajectory and Initiatives
Historical Growth: The company's historical growth is reflected in its progress through preclinical and clinical development stages.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals of its product candidates. Analyst estimates are unavailable due to the company's private status.
Recent Initiatives: Recent initiatives include advancing MBX-214 through Phase 2 clinical trials and expanding its product pipeline through the PEP platform.
Summary
MBX Biosciences is an early-stage biopharmaceutical company with a promising peptide therapeutic platform. Its success hinges on positive clinical trial outcomes and navigating the competitive landscape. The company's focus on unmet needs in endocrine disorders positions it for potential growth, but requires significant investment and carries inherent risks. The biggest risk to the company is lack of financial details which should be accounted for in any rating.
Peer Comparison
Sources and Disclaimers
Data Sources:
- MBX Biosciences website
- Industry reports
- Clinical trial databases
Disclaimers:
This analysis is based on publicly available information and limited financial data. The AI-based rating is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MBX Biosciences, Inc. Common Stock
Exchange NASDAQ | Headquaters Carmel, IN, United States | ||
IPO Launch date 2024-09-13 | CEO, President & Director Mr. Peter Kent Hawryluk MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 43 | Website https://mbxbio.com |
Full time employees 43 | Website https://mbxbio.com | ||
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.